HBOT for COVID-19 Patients

STUDY 1: The Immediate and Long-Term Advantages of Hyperbaric Oxygen Therapy for Long COVID-19 Patients

Approximately 15.1% of individuals experience Long Covid Syndrome (LCS) three months after severe SARS-CoV-2 infection, with symptoms persisting beyond 12 months. These symptoms commonly include enduring fatigue, mood fluctuations, bodily discomfort, cognitive decline, and ongoing respiratory issues. Additional persistent symptoms may encompass headaches, mental health disorders, gastrointestinal problems, sleep disturbances, hair loss, and changes in smell/taste perception.

Currently, treatment options are mainly limited to addressing symptoms, with no specific medication established. Previous research has indicated that just 10 sessions of HBOT at 2.4 ATA led to a statistically significant improvement in fatigue, cognitive function, attention, information processing, and verbal abilities.

In this study, 18 patients (aged 18-90) underwent a brief course of 10 hyperbaric sessions at 2.2 ATA and were re-evaluated three months later for LCS assessment. Encouragingly, the findings revealed significant enhancements in energy levels, physical well-being, emotional state, social interactions, and the ability to perform daily activities.

STUDY 2: The Anti-Inflammatory Advantages of Hyperbaric Oxygen Therapy Aid Long COVID Patients, Including Professional Athletes

COVID-19 presents an escalating concern for recovered patients transitioning from the acute phase to enduring long-term health issues. This condition, known as long COVID-19, affects individuals across various health spectrums, including those with chronic illnesses, the generally healthy, and even professional athletes.

“Long COVID-19 manifests with systemic inflammation and persistent symptoms like fatigue, significantly impacting daily life. Hyperbaric oxygen therapy (HBOT) has demonstrated the ability to trigger a robust anti-inflammatory response, offering potential relief for long COVID-19 patients.

“In this study, five subjects, including two patients and three athletes, underwent 30 sessions of HBOT. All participants experienced a reduction in inflammatory biomarkers, notably the athletes. These preliminary findings suggest HBOT as a promising treatment option for long COVID-19 patients.”